Developments with experimental and investigational drugs for axial spondyloarthritis

References

• Sieper J, Poddubnyy D. Axial spondyloarthritis. Lancet. 2017 Jan 19. PubMed PMID: 28110981. DOI:10.1016/S0140-6736(16)31591-4 ​​
   PubMedGoogle Scholar
• Miceli-Richard C. Enthesitis: the clue to the pathogenesis of spondyloarthritis? Joint Bone Spine. 2015 Dec;82(6):402–405. PubMed PMID: 26431931.
   PubMed Web of Science ®Google Scholar
• Wendling D. The gut in spondyloarthritis. Joint Bone Spine. 2016 Jul;83(4):401–405. PubMed PMID: 27149918.
   PubMed Web of Science ®Google Scholar
• Khan MA, Haroon M, Rosenbaum JT. Acute anterior uveitis and spondyloarthritis: more than meets the eye. Curr Rheumatol Rep. 2015 Sep;17(9):59. PubMed PMID: 26233598.
   PubMed Web of Science ®Google Scholar
• Brown MA, Kenna T, Wordsworth BP. Genetics of ankylosing spondylitis - insights into pathogenesis. Nat Rev Rheumatol. 2016 Feb;12(2):81–91. PubMed PMID: 26439405.
   PubMed Web of Science ®Google Scholar
• Sieper J, Poddubnyy D. New evidence on the management of spondyloarthritis. Nat Rev Rheumatol. 2016 May;12(5):282–295. PubMed PMID: 27052489.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Ramiro S, Landewe R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017 Jan:13. PubMed PMID: 28087505. DOI:10.1136/annrheumdis-2016-210770
   Web of Science ®Google Scholar
• Rudwaleit M, van der Heijde D, Landewe R, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009 Jun;68(6):777–783. PubMed PMID: 19297344.
   PubMed Web of Science ®Google Scholar
• Rudwaleit M, van der Heijde D, Landewe R, et al. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis. 2011 Jan;70(1):25–31. PubMed PMID: 21109520.
   PubMed Web of Science ®Google Scholar
• van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984 Apr;27(4):361–368. PubMed PMID: 6231933.
   PubMed Web of Science ®Google Scholar
• Corbett M, Soares M, Jhuti G, et al. Tumour necrosis factor-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis: a systematic review and economic evaluation. Health Technol Assess. 2016 Feb;20(9):1–334, v–vi. PubMed PMID: 26847392; PubMed Central PMCID: PMCPMC4781282.
   PubMed Web of Science ®Google Scholar
• Spadaro A, Lubrano E, Marchesoni A, et al. Remission in ankylosing spondylitis treated with anti-TNF-alpha drugs: a national multicentre study. Rheumatology (Oxford). 2013 Oct;52(10):1914–1919. PubMed PMID: 23878312.
   PubMed Web of Science ®Google Scholar
• Lubrano E, Perrotta FM, Marchesoni A, et al. Remission in nonradiographic axial spondyloarthritis treated with anti-tumor necrosis factor-alpha drugs: an Italian multicenter study. J Rheumatol. 2015 Feb;42(2):258–263. PubMed PMID: 25512483.
   PubMed Web of Science ®Google Scholar
• Lubrano E, Massimo Perrotta F, Manara M, et al. Predictors of loss of remission and disease flares in patients with axial spondyloarthritis receiving antitumor necrosis factor treatment: a retrospective study. J Rheumatol. 2016 Aug;43(8):1541–1546. PubMed PMID: 27252428.
   PubMed Web of Science ®Google Scholar
• Braun J, Baraliakos X, Heldmann F, et al. Tumor necrosis factor alpha antagonists in the treatment of axial spondyloarthritis. Expert Opin Investig Drugs. 2014 May;23(5):647–659. PubMed PMID: 24654630.
   PubMed Web of Science ®Google Scholar
• Miossec P. IL-17, now an important target for treatment in arthritis! Joint Bone Spine. 2016 Dec 23. PubMed PMID: 28017822. DOI:10.1016/j.jbspin.2016.12.001
   PubMed Web of Science ®Google Scholar
• Beringer A, Noack M, Miossec P. IL-17 in chronic inflammation: from discovery to targeting. Trends Mol Med. 2016 Mar;22(3):230–241. PubMed PMID: 26837266.
   PubMed Web of Science ®Google Scholar
• Smith JA. The bench-to-bedside story of IL-17 and the therapeutic efficacy of its targeting in spondyloarthritis. Curr Rheumatol Rep. 2016 Jun;18(6):33. PubMed PMID: 27105640.
   PubMed Web of Science ®Google Scholar
• Wellcome Trust Case Control C, Australo-Anglo-American Spondylitis C, Burton PR, et al. Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet. 2007 Nov;39(11):1329–1337. PubMed PMID: 17952073; PubMed Central PMCID: PMCPMC2680141.
   PubMed Web of Science ®Google Scholar
• Australo-Anglo-American Spondyloarthritis C, Reveille JD, Sims AM, et al. Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci. Nat Genet. 2010 Feb;42(2):123–127. PubMed PMID: 20062062; PubMed Central PMCID: PMCPMC3224997.
   PubMed Web of Science ®Google Scholar
• Sherlock JP, Joyce-Shaikh B, Turner SP, et al. IL-23 induces spondyloarthropathy by acting on ROR-gammat+ CD3+CD4-CD8- entheseal resident T cells. Nat Med. 2012 Jul 01;18(7):1069–1076. PubMed PMID: 22772566.
   PubMed Web of Science ®Google Scholar
• DeLay ML, Turner MJ, Klenk EI, et al. HLA-B27 misfolding and the unfolded protein response augment interleukin-23 production and are associated with Th17 activation in transgenic rats. Arthritis Rheum. 2009 Sep;60(9):2633–2643. PubMed PMID: 19714651; PubMed Central PMCID: PMCPMC2893331.
   PubMed Web of Science ®Google Scholar
• Ruutu M, Thomas G, Steck R, et al. Beta-glucan triggers spondylarthritis and Crohn’s disease-like ileitis in SKG mice. Arthritis Rheum. 2012 Jul;64(7):2211–2222. PubMed PMID: 22328069.
   PubMed Web of Science ®Google Scholar
• Shen H, Goodall JC, Hill Gaston JS. Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis. Arthritis Rheum. 2009 Jun;60(6):1647–1656. PubMed PMID: 19479869.
   PubMed Web of Science ®Google Scholar
• Kenna TJ, Davidson SI, Duan R, et al. Enrichment of circulating interleukin-17-secreting interleukin-23 receptor-positive gamma/delta T cells in patients with active ankylosing spondylitis. Arthritis Rheum. 2012 May;64(5):1420–1429. PubMed PMID: 22144400.
   PubMed Web of Science ®Google Scholar
• Jansen DT, Hameetman M, van Bergen J, et al. IL-17-producing CD4+ T cells are increased in early, active axial spondyloarthritis including patients without imaging abnormalities. Rheumatology (Oxford). 2015 Apr;54(4):728–735. PubMed PMID: 25288779.
   PubMed Web of Science ®Google Scholar
• Ridley A, Hatano H, Wong-Baeza I, et al. Activation-induced killer cell immunoglobulin-like receptor 3DL2 binding to HLA-B27 licenses pathogenic T cell differentiation in spondyloarthritis. Arthritis Rheumatol. 2016 Apr;68(4):901–914. PubMed PMID: 26841353; PubMed Central PMCID: PMCPMC4855641.
   PubMed Web of Science ®Google Scholar
• Appel H, Maier R, Wu P, et al. Analysis of IL-17(+) cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response. Arthritis Res Ther. 2011 Jun 20;13(3):R95. PubMed PMID: 21689402; PubMed Central PMCID: PMCPMC3218910.
   PubMed Web of Science ®Google Scholar
• Noordenbos T, Yeremenko N, Gofita I, et al. Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritis. Arthritis Rheum. 2012 Jan;64(1):99–109. PubMed PMID: 21968742.
   PubMed Web of Science ®Google Scholar
• Ciccia F, Guggino G, Rizzo A, et al. Type 3 innate lymphoid cells producing IL-17 and IL-22 are expanded in the gut, in the peripheral blood, synovial fluid and bone marrow of patients with ankylosing spondylitis. Ann Rheum Dis. 2015 Sep;74(9):1739–1747. PubMed PMID: 25902790.
   PubMed Web of Science ®Google Scholar
• Appel H, Maier R, Bleil J, et al. In situ analysis of interleukin-23- and interleukin-12-positive cells in the spine of patients with ankylosing spondylitis. Arthritis Rheum. 2013 Jun;65(6):1522–1529. PubMed PMID: 23508523.
   PubMed Web of Science ®Google Scholar
• Wendling D, Guillot X, Prati C. The IL-23/Th 17 pathway in spondyloarthritis: the royal road? Joint Bone Spine. 2015 Jan;82(1):1–4. PubMed PMID: 25245641.
   PubMed Web of Science ®Google Scholar
• Wendling D. An overview of investigational new drugs for treating ankylosing spondylitis. Expert Opin Investig Drugs. 2016;25(1):95–104. PubMed PMID: 26561014.
   PubMed Web of Science ®Google Scholar
• Song X, He X, Li X, et al. The roles and functional mechanisms of interleukin-17 family cytokines in mucosal immunity. Cell Mol Immunol. 2016 Jul;13(4):418–431. PubMed PMID: 27018218; PubMed Central PMCID: PMCPMC4947810.
   PubMed Web of Science ®Google Scholar
• Baeten D, Sieper J, Braun J, et al. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med. 2015 Dec 24;373(26):2534–2548. PubMed PMID: 26699169.
   PubMed Web of Science ®Google Scholar
• Deodhar AA, Dougados M, Baeten DL, et al. Effect of secukinumab on patient-reported outcomes in patients with active ankylosing spondylitis: a phase III randomized trial (MEASURE 1). Arthritis Rheumatol. 2016 Dec;68(12):2901–2910. PubMed PMID: 27390130; PubMed Central PMCID: PMCPMC5132041.
   PubMed Web of Science ®Google Scholar
• Braun J, Baraliakos X, Deodhar A, et al. Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study. Ann Rheum Dis. 2016 Dec 13. PubMed PMID: 27965257. DOI:10.1136/annrheumdis-2016-209730
   Web of Science ®Google Scholar
• Braun J, Baraliakos X, Kiltz U. Secukinumab (AIN457) in the treatment of ankylosing spondylitis. Expert Opin Biol Ther. 2016;16(5):711–722. PubMed PMID: 26982813.
   PubMed Web of Science ®Google Scholar
• Sieper J, Deodhar A, Marzo-Ortega H, et al. Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 study. Ann Rheum Dis. 2017 Mar;76(3):571–592. PubMed PMID: 27582421.
   PubMed Web of Science ®Google Scholar
• Baraliakos X, Borah B, Braun J, et al. Long-term effects of secukinumab on MRI findings in relation to clinical efficacy in subjects with active ankylosing spondylitis: an observational study. Ann Rheum Dis. 2016 Feb;75(2):408–412. PubMed PMID: 26248638.
   PubMed Web of Science ®Google Scholar
• Larrick JW, Alfenito MR, Scott JK, et al. Antibody engineering & therapeutics 2016: the Antibody Society’s Annual Meeting; 2016 Dec 11-15; San Diego, CA. MAbs. 2016 Nov/Dec; 8(8):1425-1434. PubMed PMID: 27557809; PubMed Central PMCID: PMCPMC5098447. DOI:10.1080/19420862.2016.1227665
   Google Scholar
• Glatt S, Helmer E, Haier B, et al. First-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasis. Br J Clin Pharmacol. 2016 Nov:13. PubMed PMID: 27859546. DOI:10.1111/bcp.13185
   PubMed Web of Science ®Google Scholar
• Chernyaeva E, Eremeeva A, Galustyan A, et al. FRI0010 pharmacokinetics, safety and tolerance of BCD-085, a novel IL-17 inhibitor, based on the results of phase 1 clinical study in healthy volunteers. Ann Rheum Dis. 2016;75(Suppl 2):429–429.
   Web of Science ®Google Scholar
• Siliq (brodalumab) approved by the US FDA for adult patients with moderate-to-severe plaque psoriasis Astrazeneca Websites. 2017 [cited 2017 Mar 10]. Available from: https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/siliq-brodalumab-approved-by-the-US-FDA-for-adult-patients-with-moderate-to-severe-plaque-psoriasis-16022017.html
   Google Scholar
• Duvallet E, Semerano L, Assier E, et al. Interleukin-23: a key cytokine in inflammatory diseases. Ann Med. 2011 Nov;43(7):503–511. PubMed PMID: 21585245.
   PubMed Web of Science ®Google Scholar
• Poddubnyy D, Hermann KG, Callhoff J, et al. Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS). Ann Rheum Dis. 2014 May;73(5):817–823. PubMed PMID: 24389297.
   PubMed Web of Science ®Google Scholar
• Deodhar AB, Boehncke WH, Dong B, et al. Efficacy and safety results of guselkumab, an anti-IL23 monoclonal antibody, in patients with active psoriatic arthritis over 24 weeks: a phase 2a, randomized, double-blind, placebo-controlled study [abstract]. Arthritis Rheumatol. 2016;68(suppl 10):4L.
   Google Scholar
• Yiu ZZ, Warren RB. The potential utility of tildrakizumab: an interleukin-23 inhibitor for the treatment of psoriasis. Expert Opin Investig Drugs. 2017 Feb;26(2):243–249. PubMed PMID: 28042732.
   PubMed Web of Science ®Google Scholar
• Dyke HJ, Montana JG. Update on the therapeutic potential of PDE4 inhibitors. Expert Opin Investig Drugs. 2002 Jan;11(1):1–13. PubMed PMID: 11772317.
   PubMed Web of Science ®Google Scholar
• Schafer PH, Parton A, Gandhi AK, et al. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol. 2010 Feb;159(4):842–855. PubMed PMID: 20050849; PubMed Central PMCID: PMCPMC2829210.
   PubMed Web of Science ®Google Scholar
• Pathan E, Abraham S, Van Rossen E, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis. Ann Rheum Dis. 2013 Sep 01;72(9):1475–1480. PubMed PMID: 22984171.
   PubMed Web of Science ®Google Scholar
• Semerano L, Decker P, Clavel G, et al. Developments with investigational Janus kinase inhibitors for rheumatoid arthritis. Expert Opin Investig Drugs. 2016 Dec;25(12):1355–1359. PubMed PMID: 27748152.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Lenardo MJ, Baltimore D. 30 years of NF-kappaB: a blossoming of relevance to human pathobiology. Cell. 2017 Jan 12;168(1–2):37–57. PubMed PMID: 28086098; PubMed Central PMCID: PMCPMC5268070.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Deodhar A, Wei JC, et al. Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study. Ann Rheum Dis. 2017 Jan 27. PubMed PMID: 28130206. DOI:10.1136/annrheumdis-2016-210322
   Google Scholar
• Paramarta JE, Turina MC, Noordenbos T, et al. A proof-of-concept study with the tyrosine kinase inhibitor nilotinib in spondyloarthritis. J Transl Med. 2016 Oct 27;14(1):308. PubMed PMID: 27784336; PubMed Central PMCID: PMCPMC5081668.
   PubMed Web of Science ®Google Scholar
• Orlando A, Orlando R, Ciccia F, et al. Clinical benefit of vedolizumab on articular manifestations in patients with active spondyloarthritis associated with inflammatory bowel disease. Ann Rheum Dis. 2017 Jan 17. PubMed PMID: 28096071. DOI:10.1136/annrheumdis-2016-211011
   PubMedGoogle Scholar
• Varkas G, Thevissen K, De Brabanter G, et al. An induction or flare of arthritis and/or sacroiliitis by vedolizumab in inflammatory bowel disease: a case series. Ann Rheum Dis. 2017 May;76(5):878–881. PubMed PMID: 27899374.
   PubMed Web of Science ®Google Scholar
• Schett G, Elewaut D, McInnes IB, et al. How cytokine networks fuel inflammation: toward a cytokine-based disease taxonomy. Nat Med. 2013 Jul;19(7):822–824. PubMed PMID: 23836224.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Puig L, Gottlieb AB, et al. Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2). Ann Rheum Dis. 2016 Nov;75(11):1984–1988. PubMed PMID: 27098404.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Mease PJ, Reimold AM, et al. Secukinumab for long-term treatment of psoriatic arthritis: a two-year followup from a phase III, randomized, double-blind placebo-controlled study. Arthritis Care Res (Hoboken). 2017 Mar;69(3):347–355. PubMed PMID: 27696786.
   PubMed Web of Science ®Google Scholar
• Hueber W, Sands BE, Lewitzky S, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012 Dec;61(12):1693–1700. PubMed PMID: 22595313; PubMed Central PMCID: PMCPMC4902107.
   PubMed Web of Science ®Google Scholar
• Dick AD, Tugal-Tutkun I, Foster S, et al. Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. Ophthalmology. 2013 Apr;120(4):777–787. PubMed PMID: 23290985.
   PubMed Web of Science ®Google Scholar
• Letko E, Yeh S, Foster CS, et al. Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy. Ophthalmology. 2015 May;122(5):939–948. PubMed PMID: 25638011.
   PubMed Web of Science ®Google Scholar
• Torres T, Romanelli M, Chiricozzi A. A revolutionary therapeutic approach for psoriasis: bispecific biological agents. Expert Opin Investig Drugs. 2016 Jul;25(7):751–754. PubMed PMID: 27153320.
   PubMed Web of Science ®Google Scholar
• Maksymowych WP, Morency N, Conner-Spady B, et al. Suppression of inflammation and effects on new bone formation in ankylosing spondylitis: evidence for a window of opportunity in disease modification. Ann Rheum Dis. 2013 Jan;72(1):23–28. PubMed PMID: 22562977.
   PubMed Web of Science ®Google Scholar
• Ramiro S, Smolen JS, Landewe R, et al. Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis. 2016 Mar;75(3):490–498. PubMed PMID: 26660203.
   PubMed Web of Science ®Google Scholar
• Jasenosky LD, Scriba TJ, Hanekom WA, et al. T cells and adaptive immunity to Mycobacterium tuberculosis in humans. Immunol Rev. 2015 Mar;264(1):74–87. PubMed PMID: 25703553.
   PubMed Web of Science ®Google Scholar